But TIGIT has not lived up to the hype, at least not yet. The most recent setback occurred just last week, when Roche reported the failure of its anti-TIGIT antibody in a Phase 3 study involving ...

ARC-7 is a Phase 2, multicenter, three-arm, randomized, open-label study evaluating the combinations of Fc-silent anti-TIGIT monoclonal antibody domvanalimab plus anti-PD1 monoclonal antibody ...

When added to GSK’s drug Jemperli, the immunotherapy, known as belrestotug and aimed at a cellular target called TIGIT, didn’t meet preset criteria for progression-free survival compared to ...

TIGIT expression can cause T cell exhaustion and NK cell immunosuppression. Thus, it is thought that targeting TIGIT could help reactivate T and NK cells while also suppressing tumor expansion.

TIGIT is a popular target in cancer therapy, and pharmaceutical companies are paying big bucks for antibodies that appear to block it. In May, Bristol Myers Squibb bought Agenus’ anti-TIGIT ...

ITOS is tantalizing, not sure if TIGIT class lives up to promise, but I believe they have the best shot on goal bc they have the only TIGIT to show mono-therapy activity, and based on the success ...

Roche said its experimental cancer immunotherapy directed against TIGIT suffered a second consecutive setback, failing to slow tumor growth in a large study involving the most common lung cancer.

Maybe TIGIT really isn't all that useful as an oncology target, and the absolute best case for it is that it crawls up to clinical significance if you manage to align everything perfectly.

While most of the attention on this trial will be directed toward the anti-TIGIT, the value and impact of etrumadenant is also up for inspection. Grossman said that Gilead is “continuing to ...

Biotech Novartis hasn't given up on TIGIT, CEO insists, as Big Pharma 'active' in cancer M&A search By James Waldron Feb 1, 2023 11:21am Novartis TIGIT immuno-oncology ...

Arcus is developing a second anti-TIGIT candidate, AB308, an Fc-enabled investigational monoclonal antibody in clinical development, with a potential focus on hematological malignancies.

FACS Figure 6. FACS assay shows that Human TIGIT, His Tag (Cat. No. TIT-H52H3) can bind to 293T cell overexpressing human CD155. The concentration of TIGIT used is 0.3 μg/mL. Table 2. Product list.